In the treatment of acute bacterial skin and skin structure infections, pooled data from 2 clinical trials (N = 1333 patients) showed that programmatic and investigator-assessed early treatment success both had a high positive predictive value (94.3%-100.0%) for late clinical cure, including among hospitalized patients. The negative predictive value of programmatic early success was <20%. These exploratory findings require prospective real-world evaluation.
Incidence of skin and soft tissue infections is rising globally [1] . In acute bacterial skin and skin structure infection (ABSSSI), several disease, organism, and host factors can cause treatment failure of the empirically selected first-line agent [1, 2] . Identifying early predictors of treatment outcome could help guide clinical decision making, including discharge of hospitalized patients. Such decisions are often made after 2-3 days of treatment, coinciding with microbiologic culture results [3, 4] . In community-acquired pneumonia, another acute bacterial infection, early clinical stabilization results in better treatment outcomes [5] .
To further explore this issue in ABSSSI, we retrospectively analyzed data from 2 large randomized controlled trials comparing tedizolid and linezolid to assess whether early clinical response at 48-72 hours could predict late treatment outcome 1-2 weeks after end of therapy.
METHODS
We used data from 2 phase 3 trials (ESTABLISH-1 and ESTABLISH-2) comparing tedizolid phosphate (200 mg intravenous or oral once daily, 6 days) with linezolid (600 mg intravenous or oral twice daily, 10 days) in ABSSSI. Details on study design and main results were previously published [6] [7] [8] . Clinical response was assessed early (48-72 hours after treatment initiation) and late at the posttherapy evaluation (PTE; 7-14 days after end of therapy). "Early treatment success" was defined 2 ways: programmatic (≥20% reduction in lesion area from baseline) and investigator assessed ("improving" or "stable" clinical condition compatible with study therapy continuation). Lesion area was defined as longest head-to-toe length × widest perpendicular width of erythema (ESTABLISH-1) or of erythema, induration, and/or edema (ESTABLISH-2). Patients without early programmatic success continued treatment, but patients not deemed "improving" or "stable" by the investigator at 48-72 hours were discontinued and considered clinical failures at subsequent visits. Late clinical cure was defined as investigator-assessed resolution/ near-resolution of disease-specific signs/symptoms at PTE, such that no further antibacterial therapy was required.
We pooled data across treatment arms and trials and retrospectively calculated the following measures for early programmatic and early investigator-assessed treatment success, with exact 95% confidence intervals derived using the ClopperPearson method:
• Table 2 ). Analyzing tedizolid and linezolid separately, by individual trial and pooling both trials, also yielded comparable results (Supplementary Tables 3-5) .
DISCUSSION
This retrospective analysis of pooled data from 2 phase 3 trials showed that in ABSSSI treated with oxazolidinones, early programmatic or clinician-assessed treatment successes at 48-72 hours after first dose were both good indicators of late clinical cure. Lack of early programmatically determined treatment success, however, was a poor indicator of late clinical failure, with many early nonresponders ultimately experiencing clinical success. This is perhaps not unexpected, since this early endpoint measures an inflammatory response whose magnitude can be influenced by a number of factors besides antibacterial treatment-for example, early surgical interventions, causative pathogens and their virulence, local and systemic comorbidity, and infection site [9] . In addition, predictive value is dependent on the prevalence of the outcome; if the incidence of failure is low, NPV will also be low. Calculating sensitivity and NPV of investigator-assessed early response was not possible, because there were no false-negative results for this measure: all early investigator-assessed nonsuccesses were censored and carried forward as failures. Our data suggest it is too early to change ABSSSI therapy at 2-3 days if there is no reduction in lesion area by that time, at least in the case of empiric oxazolidinone treatment. Instead, it may be prudent to schedule frequent follow-up visits, to allow for timely therapeutic adjustments if lack of response persists for another 24 hours. Overall results were independent of hospitalization status, definition of early success, type of ABSSSI, and the specific oxazolidinone. Differences in point estimates for specificity, where the denominator is the number of late clinical failures, are likely due to small patient numbers, also reflected in the wide and overlapping confidence intervals. In a previous real-world retrospective cohort study, ABSSSI patients lacking clinical success at day 3 had significantly higher healthcare costs and longer treatment duration [10] . However, that study used a different definition of early success (ie, cessation of lesion spread and absence of fever) no longer recommended in guidelines for conducting ABSSSI trials. It also reported markedly lower rates of early treatment success than ESTABLISH-1 and -2, and the lower prevalence of early success was likely reflected in worse outcomes over time.
Our results indicating high PPV of programmatically determined early success for late clinical cure are in accordance with historical evidence that the largest effects of antibacterial therapy usually occur early during treatment [11] . They also align with recent ABSSSI clinical trials comparing various antibacterial treatment strategies; all reported high concordance between early treatment success based on lesion area and late clinical cure [8, 12, 13] . Our results provide further support for using early response based on lesion area measurement as an endpoint in ABSSSI clinical trials. However, because lesion area is rarely measured in clinical practice, these findings have limited value to inform disease management decisions outside of research settings. Of much greater practical interest is our observation that patients assessed by the treating clinician as improving or stable at 48-72 hours had a high likelihood of clinical cure (>94%) at the PTE visit. The real-world applicability of this finding, particularly in hospitalized patients, requires additional investigation in properly designed studies. If confirmed, a clinician assessment of early treatment success might help identify ABSSSI patients benefiting from shorter therapy durations, step-down therapy to oral or narrower-spectrum agents, and/or early hospital discharge. These should be prospective, real-world studies, using robust methodology with strictly defined outcomes and treatment strategies reflective of best practice.
Our observations are likely generalizable to other antibacterial classes, given that several other recent ABSSSI trials also reported high concordance between early success and late clinical cure and low concordance between early nonsuccess and late treatment failure [8, 12, 13] . Nevertheless, the results must be interpreted with caution, given the post hoc, hypothesis-generating nature of this work based on phase 3 trials with relatively narrow eligibility criteria. Another possible limitation is uncertainty about the optimum approach to measuring lesion size. However, several studies have now shown that defining lesion area as length × width of erythema, induration, and edema, measured using a flexible plastic ruler, is a reliable and highly reproducible approach [14] [15] [16] . A final limitation is potential selection bias in our analysis, by having to exclude patients with missing response data. Such selection bias is negligible, however, since approximately 90% of all ITT patients were evaluable for our analyses. In addition, most discontinuations were not of a clinical nature: only 43 of 1333 ITT patients were unevaluable for reasons that could have contributed potential bias (ie, treatment failure, adverse events, gram-negative infection, or other) [8] . Subgroup and sensitivity analyses were consistent with the main analysis, further demonstrating the robustness of our findings.
In conclusion, this exploratory analysis suggests that in ABSSSI, a physician determination of treatment success, based on symptom assessment without comprehensive lesion area measurements 2-3 days after therapy initiation, might help predict overall clinical cure with the empiric regimen. Integrating this information into real-world clinical decision making is worthy of further prospective study. In addition, our results highlight the need for new methods to achieve improved accuracy in predicting overall clinical failure; combining patient-reported pain and clinician-reported outcomes may be one approach to improve the NPV of early response assessments without decreasing PPV [13, 15] .
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